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In recent studies, we have identified several highly potent all-trans-retinoic acid (ATRA) metabolism blocking agents (RAMBAs). On
the basis of previous effects of liarozole (a first-generation RAMBA) on the catabolism of ATRA and on growth of rat Dunning
R3227G prostate tumours, we assessed the effects of our novel RAMBAs on human prostate tumour (PCA) cell lines. We examined
three different PCA cell lines to determine their capacity to induce P450-mediated oxidation of ATRA. Among the three different cell
lines, enhanced catabolism was detected in LNCaP, whereas it was not found in PC-3 and DU-145. This catabolism was strongly
inhibited by our RAMBAs, the most potent being VN/14-1, VN/50-1, VN/66-1, and VN/69-1 with IC50 values of 6.5, 90.0, 62.5, and
90.0nM, respectively. The RAMBAs inhibited the growth of LNCaP cells with IC50 values in the mM-range. In LNCaP cell proliferation
assays, VN/14-1, VN/50-1, VN/66-1, and VN/69-1 also enhanced by 47-, 60-, 70-, and 65-fold, respectively, the ATRA-mediated
antiproliferative activity. We then examined the molecular mechanism underlying the growth inhibitory properties of ATRA alone
and in combination with RAMBAs. The mechanism appeared to involve the induction of differentiation, cell-cycle arrest, and
induction of apoptosis (TUNEL), involving increase in Bad expression and decrease in Bcl-2 expression. Treatment of LNCaP
tumours growing in SCID mice with VN/66-1 and VN/69-1 resulted in modest but statistically significant tumour growth inhibition of
44 and 47%, respectively, while treatment with VN/14-1 was unexpectedly ineffective. These results suggest that some of our novel
RAMBAs may be useful agents for the treatment of prostate cancer.
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Retinoids, including vitamin A and its natural and synthetic
analogues, have been used as experimental treatments in cancer
patients for the last 30 years (Smith et al, 1992a; Sporn et al, 1994;
Lotan, 1996). Retinoic acids play a role in proliferation, differentia-
tion, metabolism, reproduction, and morphogenesis (De Luca et al,
1995; Miller, 1998). Additionally, one such natural analogue, all-
trans-retinoic acid (ATRA), has been used successfully in the
treatment of acute promyelocytic leukemia (APL) (Huang et al,
1988; Smith et al, 1992b). ATRA acts by binding to nuclear retinoic
acid receptors (RARs), of which there are three subtypes, RAR-a,-
b, and -g. (Chambon et al, 1991; Mangelsdorf et al, 1994).
There are numerous evidence for the role of the retinoids,
including ATRA, in prostate cancer (PCA). Human, animal, and
epidemiological studies suggest that retinoid deficiency plays a
role in PCA development (Lasnitzki and Goodman, 1974; Hayes
et al, 1988; Carter et al, 1990; Reichman et al, 1990; Hanchette and
Schwartz, 1992; Peehl et al, 1993). Pasquali et al demonstrated that
levels of endogenous ATRA are five to eight times lower in human
PCA tissues than in normal prostate tissues (Pasquali et al, 1996).
Nagy et al (1996) demonstrated that the expression of Bcl-2, an
antiapoptotic protein, was regulated by ATRA. Expression of Bcl-2
is also associated with the development of androgen resistance and
invasiveness of androgen-independent PCA (McDonnell et al,
1992; Raffo et al, 1995; McDonnell et al, 1997). In addition, other
groups have demonstrated the role of ATRA and its synthetic
derivatives on growth of both the prostate gland and PCA cell lines
(Pollard and Luckert, 1991; Pienta et al, 1993; Young et al, 1994;
Gao et al, 1999).
However, the therapeutic effects of the retinoids are limited
owing to their rapid in vivo metabolism (Muindi et al, 1992). The
first step in the metabolism of ATRA is catalysed by CYP26A1, a
cytochrome P450 enzyme, where the C-4 of ATRA is hydroxylated
to 4-hydroxy-ATRA, which can then be oxidized to 4-oxo-ATRA,
which undergoes further reactions to yield more polar metabolites
(Frolik et al, 1979). CYP26 family appears to be the most dedicated
ATRA 4-hydroxylase (Njar, 2002, 2006; Marill et al, 2003). Other
CYPs, including CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP3A4,
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sand CYP3A7 are ATRA 4-hydroxylases and are involved in ATRA
metabolism as well, although their specificity for ATRA is low
(Njar, 2002, 2006; Marill et al, 2003). PCA cells may develop
resistance to ATRA using this mechanism as demonstrated by APL
patients who relapse within 3–15 months after first remission with
ATRA therapy (Norum, 1993).
Although research to date has concentrated on the use of
exogenous retinoids, a potential new approach to the treatment
and prevention of cancer is the use of retinoic acid metabolism
blocking agents (RAMBAs), which increase levels of retinoic acid
within tumour cells by blocking their metabolism (Wouters, 1994;
Miller, 1998; Njar, 2002, 2006). Additionally, it has been shown that
certain retinoids, including ATRA, are capable of directing
neoplastic cells to the normal phenotype of morphological
maturation and loss of proliferative capacity, thereby reversing
or suppressing developing lesions and preventing cancer invasion
(Sporn et al, 1976; Sporn, 1991; Lippman et al, 1994; Moon et al,
1994; Lotan, 1996).
We have designed and synthesized a number of novel RAMBAs
to inhibit CYP26 and the other ATRA 4-hydroxylases with the goal
of preventing in vivo metabolism and thereby increasing the
endogenous levels of ATRA (Njar et al, 2000; Patel et al, 2004).
These novel RAMBAs have been described as atypical, owing to
their multiple biological activities especially in MCF-7 and T47D
human breast cancer cells (Patel et al, 2004). The effects of the
RAMBAs (VN/14-1, VN/50-1, VN/66-1, and VN/69-1; Figure 1),
alone and in combination with ATRA, on ATRA metabolism, and
on PCA cell viability, apoptosis, cell cycle, and differentiation, and
on in vivo antitumour studies have been examined. In addition, the
molecular mechanisms underlying the biological activities of these
agents were also investigated. These studies are the basis of this
report.
MATERIALS AND METHODS
Drug preparations
We have previously published the syntheses of the RAMBAs used
in this study (Patel et al, 2004). All-trans-retinoic acid (ATRA) and
the RAMBAs were dissolved in 95% ethanol and stored at  201Ci n
the dark. The concentrations (1 and 5mM) of the various agents
(retinoids and RAMBAs) are typical for retinoid cancer cells
inhibitory studies (Wu et al, 2001). All chemicals were purchased
from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise
noted.
Cell culture
Prostate cancer cell lines, LNCaP, PC3, and DU145, were incubated
in the RPMI 1640 medium (Gibco-Invitrogen, Carlsbad, CA, USA)
preparation containing 10% FBS (Hyclone, Logan, UT, USA) and
1% penicillin–streptomycin solution (Gibco-Invitrogen, Carlsbad,
CA, USA) at 371C and 5% CO2. All cells were subcultured weekly.
LNCaP cells used in the following studies were performed between
passages 7–20.
Preparation of cellular CYP26 microsomes
The procedure described by Han and Choi (1996) was used.
Briefly, LNCaP cells were incubated with 1mM ATRA for 24h to
induce the CYP26 enzyme. The cells were trypsinised and rinsed
with phosphate-buffered saline (PBS) (Life Technologies, Grand
Island, NY, USA) by centrifugation for 5min at 5000 g at room
temperature. The cells were resuspended in homogenate buffer
(0.5 M sucrose, 10mM Tris-Cl (pH 7.4), 1mM ethylenediamine
tetraacetate (EDTA), 1mM phenylmethylsulfonylfluoride,
0.1mgml
 1 leupeptin, and 0.04Uml
 1 aprotonin), homogenised,
and then centrifuged at 9000 g for 10min at 41C. The
supernatant was then centrifuged at 100000 g for 45min at
41C. The pellet was resuspended in storage buffer (0.25 M sucrose,
10mM Tris-Cl (pH 7.4), 1mM EDTA, 1mM phenylmethylsulfonyl-
fluoride, 0.1mgml
 1 leupeptin, and 0.04Uml
 1 aprotonin) and
stored at  201C.
Cellular microsomal CYP26 assay
The procedure for the hepatic microsomal enzyme assay (for
ATRA 4-hydroxylases) was used where 100ml of cellular CYP26
microsomes (500mgml
 1 dissolved in storage buffer) was sub-
stituted for 100ml of hepatic microsomes. The retinoid products
were extracted, processed, and analysed by HPLC as previously
described (Patel et al, 2004).
Cellular CYP26 assay
As modified from a procedure described by Wouters et al (1992),
approximately 10
6 LNCaP cells were incubated with 1mM ATRA for
24h to induce the CYP26 enzyme. Following ATRA treatment, the
LNCaP cells were incubated with 0.1 or 0.8mM [11,12-
3H]-ATRA
(PerkinElmer Life and Analytical Sciences, Inc., Boston, MA, USA)
for 5h. Following the 5h incubation, the medium was collected
and the cells were trypsinised and collected. The retinoid products
were extracted, processed, and analysed by HPLC as previously
described (Patel et al, 2004).
WST-1 cell viability assay
To measure cell viability, 24-well plates were coated with a 0.05%
poly-L-lysine solution for 30min. The wells were then washed with
sterilised dH2O. LNCaP cells (1 10
4) were seeded in the plates
and maintained in RPMI 1640 medium (Gibco-Invitrogen,
Carlsbad, CA, USA). The cells were allowed to attach for 36h.
After attachment, fresh media was added and the cells were treated
with a concentration range of either ATRA or each of the RAMBAs
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Figure 1 Chemical structures of RAMBAs, VN/14-1, VN/50-1, VN/66-1, and VN/69-1 and 4-HPR.
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sfor 6 days. The media was changed every 3 days. On the day the
assay was performed, the media was removed and 1ml of a stock
solution of WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) cell proliferation reagent
(Boehringer Mannheim, Indianapolis, IN, USA), diluted 1:10 in
RPMI 1640 medium (without FBS), was added to each well. The
plates were incubated at 371C for 3h. The media was then removed
and 500ml of DMSO was added and agitated vigorously for 5min.
The slightly red tetrazolium salt WST-1 is reduced to a dark red,
water-soluble formazan product by mitochondrial dehydrogenase
from living cells, which gives absorbance at a wavelength of
450nm.
Differentiation assay (Western-blot analysis of
cytokeratins 8/18)
LNCaP cells were incubated in the RPMI 1640 medium (Gibco-
Invitrogen, Carlsbad, CA, USA) preparation containing 1mM ATRA
alone or in combination with 1mM of each of the RAMBAs for 6
days. LNCaP cells were scraped with 1.5ml of PBS. The cells were
collected by centrifugation, resuspended in ice-cold cell lysis buffer
(0.1 M Tris-HCl, 0.5% Triton X-100, and protease inhibitor cocktail
(Boehringer, Indianapolis, IN, USA)), and sonicated. The homo-
genates were incubated on ice for 30min, subjected to centrifuga-
tion at 13000 g for 30min, and the supernatants were separated
and stored at  801C until use. Protein concentrations were
determined by the Bradford method using a Bio-Rad kit (Hercules,
CA, USA). A measure of 50mg of cell lysate was subjected to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–
PAGE) using the Mini-PROTEAN3 electrophoresis module assem-
bly (Bio-Rad, Hercules, CA, USA) at 60V at room temperature.
The separated lysates on 10% SDS–PAGE gel were transferred
onto Hybond ECL nitrocellulose membrane (Amersham, Arlington
Heights, IL, USA) overnight at 20V at 41C. Western-blot analysis
was performed on the nitrocellulose membrane. The membrane
was blocked for 1h in 10% nonfat dried milk and PBS containing
0.5% Tween 20 (PBS-T) at room temperature. Following washing
in PBS-T, the membrane was incubated with mouse monoclonal
IgG antibody to cytokeratin 8/18 or b-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA and Oncogene Research
Products, Boston, MA, USA, respectively) dissolved in 10% nonfat
dried milk (1:5000 or 1:10000), respectively) for lh at room
temperature. Following washing, the membrane was incubated
with horseradish peroxidase-linked anti-mouse IgG antibody
(Amersham, Arlington Heights, IL, USA and Oncogene Research
Products, Boston, MA, USA, respectively) dissolved in 10% nonfat
dried milk (1:1000) for 1h at room temperature. The membrane
was incubated in 4ml ECL Western Blotting Analysis System
(Amersham, Arlington Heights, IL, USA) for 1min at room
temperature. The membrane was resolved on chemiluminescence
film (Amersham Hyperfilm High Performance chemiluminescence
film, Arlington Heights, IL, USA) and the film was developed using
an X-ray developer (M35A X-OMAT Processor, Eastman Kodak
Company, Rochester, NY, USA). The intensity of the bands on film
was analysed using ImageQuant 5.0 software (Amersham, Arling-
ton Heights, IL, USA). The band intensity corresponds to the level
of protein expression of cytokeratin 8/18, which is shown to be
expressed in differentiated cells of epithelial origin (Peehl et al,
1993; Hsieh et al, 1995).
Western-blot analysis of Bad and Bcl-2
The Western-blot protocol described for cytokeratins 8/18 was
followed with some exceptions. Cell lysates (50mg) were separated
on a 15% SDS–PAGE gel. All washing was performed using TBS
containing 1% Tween 20 (TBS-T). Blocking was performed using
5% milk in TBS-T. Incubations were performed using rabbit
monoclonal IgG antibody to Bad and Bcl-2 (1:1000), as well as
horseradish peroxidase-linked anti-rabbit IgG antibodies (1:2000)
(Cell Signaling Technology, Beverly, MA, USA).
TUNEL (terminal deoxynucleotidyl transferase-mediated
dUTP nick end labelling) assay
A total of 4000 LNCaP cells were plated on each well of an eight-
well Lab-Tek II
s chamber slide (Nalge Nunc International,
Naperville, IL, USA). The LNCaP cells were then treated with
either 1 or 5mM of ATRA or RAMBA for 6 days. Cells were then
fixed in 4% paraformaldehyde solution in dH2O. The cells were
then processed and stained with FITC (fluorescein isothiocyanate)
according to kit instructions (In situ cell death detection kit, AP,
Roche Diagnostics Corp., Indianapolis, IN, USA). The FITC-
stained cells are then mounted with VectorShield
s mounting
medium for fluorescence with DAPI (40,6-diamidine-20-phenylin-
dole dihydrochloride) nuclear stain (Vector Laboratories, Inc.,
Burlingame, CA, USA) and covered with ApopTag
s plastic
coverslips (Intergen Company, Purchase, NY, USA). The slides
were then examined under fluorescence microscopy (Eclipse E400,
Nikon, Inc., Melville, NY, USA) and counted using SPOT
Advance
s 3.5 software (Diagnostic Instruments, Inc., Sterling
Heights, MI, USA).
Cell-cycle analysis
LNCaP cells were treated with 1 or 5mM of ATRA or each of the
RAMBAs for 6 days. The cells were trypsinised and washed twice in
PBS (Life Technologies, Grand Island, NY, USA). The cells were
fixed by adding 70% ethanol and stored at  201C until staining.
The cells were washed twice in PBS. A volume of 1ml of a
propidium iodide (PI) solution (50mgml
 1 in PBS) and 500mlo f
an RNase stock solution (100mgml
 1) were added to the cells and
incubated for 1h in the dark. Approximately 10
4 stained cells were
then analysed by flow cytometry (Becton Dickenson FACScan,
Franklin Lakes, NJ, USA). The percentages of cells in G0/G1, S, and
G2/M phases of the cell cycle as well as percentage of apoptotic
cells (sub G0/G1) were determined using MODFIT LT software
(Verity Software House, San Jose, CA, USA). The percentages of
cells in G0/G1, S, and G2/M phases of the cell cycle were obtained
from diploid cells in the sample and the percentage of apoptotic
cells (sub G0/G1) was obtained from total cells minus the debris.
In vivo antitumour studies (LNCaP human prostate
carcinoma xenograph mice model)
All animal studies were performed according to the guidelines and
approval of the Animal Care Committee of the University of
Maryland School of Medicine, and were consistent with United
Kingdom Coordinating Committee on Cancer Research guidelines
for the welfare of animals in experimental neoplasia. The
procedure was modified from Grigoryev et al (1999). Briefly,
LNCaP cells were trypsinised, counted, and suspended in Matrigel
(2 10
7cellsml
 1) (Fisher Scientific International, Inc., Hampton,
NH, USA). Male SCID mice of 4–6 weeks of age were obtained
from the National Cancer Institute (Frederick, MD, USA). Each
mouse was inoculated s.c. with 0.1ml of the cell suspension at two
sites in the flank. The size of the tumours was determined by
measuring the tumour volumes using calipers. Tumour volumes
were calculated using the formula V¼4/3 p r1
2 r2(r1or2).
The tumours were allowed to develop to approximately 100mm
3
before treatment. The mice were treated with 10mgkg
 1 (which is
equivalent to 0.033mmolkg
 1) of ATRA or an equivalent dose to
0.033mmolkg
 1 of each RAMBA (VN/14-1, VN/50-1, VN/66-1,
and VN/69-1) dissolved in hydroxypropyl-b-cellulose (HPC, 0.3%
in saline). Tumour volumes were measured twice weekly and
weights of animals were taken weekly after the initiation of
treatment. The mice were subjected to 6 weeks of treatment. The
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smice were then killed and the tumours were excised, weighed, and
stored at  801C until analysis. Additionally, the plasma was
collected with 50IU of heparin and stored at  801C until analysis.
Statistical analysis
One-way analysis of variance (ANOVA) with post test, which was
the Bonferroni multiple comparisons test, was performed to
compare all pairs of treatment groups using InStat
s 3 (GraphPad
Software, Inc., San Diego, CA, USA). A Po0.05 was considered
significant.
RESULTS
ATRA metabolism is inducible in LNCaP cells but not in
PC3 and DU145 cells
To assess the induction of ATRA metabolism in LNCaP, PC-3 and
DU145 prostate cells, these cells were pre-incubated with 1mM
ATRA for various time points from 4 to 48h and then further
incubated with 0.8mM [11,12-
3H]-ATRA for 5h to measure ATRA
metabolism. Our results show that LNCaP cells were induced by
ATRA and were able to metabolise [11,12-
3H]-ATRA to more polar
products from the 4 to 48h time points with maximum metabolism
occurring at 36h (Figure 2). PC-3 cells did not show any
metabolism of [11,12-
3H]-ATRA from these time points (Figure 2)
and also up to 9 days (data not shown). DU145 cells were able to
metabolise [11,12-
3H]-ATRA from the 4 to 48h time points
(Figure 2); however, this metabolism was not enhanced despite
ATRA treatment. As only the LNCaP cell line was able to
metabolise ATRA, it was utilised in subsequent cellular assays.
Inhibition of ATRA metabolism in intact LNCaP cells
(cellular assay)
To assess the ability of our novel RAMBA to inhibit ATRA
metabolism in intact cells, we used VN/14-1, VN/50-1, VN/66-1,
and VN/69-1 to evaluate their inhibitory potencies in LNCaP cells.
Human LNCaP carcinoma cells cultured under control conditions
are unable to metabolise ATRA into more polar metabolites (data
not shown). However, after pretreatment with 1mM ATRA for
12–15h, the cells show extensive ATRA metabolism (Figure 3A),
converting ATRA into highly polar metabolites (HPM, retention
time, Rt¼3–6min), and prominent metabolites of medium
polarity (MMP, Rt¼8–12min), including 4-oxo and 4-hydroxy-
ATRA. ATRA metabolism is inhibited dose dependently by VN/14-
1 (Figures 3B–D). Identical results were also obtained with the
other three compounds tested. The IC50 values for these
compounds were determined from dose–response curves and
are presented in Table 1. The compounds inhibited intracellular
ATRA metabolism with decreasing activity in the order: VN/14-
14VN/66-14VN/50-1¼VN/69-1. Compound VN/14-1 was the
most active with an IC50 value of 6.571.5nM. VN/50-1 also
inhibited ATRA metabolism of microsomes prepared from T47D
cells previously exposed to ATRA with an IC50 value of
7.071.2nM, which is of about a 13-fold higher potency compared
to the cellular IC50 value. Although the other inhibitors were not
evaluated using microsomal preparations, it is likely that they may
exhibit similar higher potencies.
Effects of the RAMBAs alone and in combination with
ATRA on LNCaP cell growth
Given the retinoidal nature of our RAMBAs it seemed logical to
investigate their effects on the growth of LNCaP cancer cells. The
antiproliferative effect of ATRA was also studied for comparison
using a WST assay. Continuous exposure of LNCaP cells to various
doses of the RAMBAs and ATRA for 6 days led to dose-dependent
inhibition of cell growth as shown in Figure 4. The calculated IC50
values (defined as the concentration of compounds required to
inhibit cell growth by 50%) from these dose–response curves are
presented in Table 1 and show that all RAMBAs are modest
inhibitors (IC50¼4.5–10.0mM) of LNCaP cell proliferation and
comparable to the potency of ATRA (IC50¼4.3mM).
The ability of each of these RAMBAs to enhance the
antiproliferative activity of ATRA in LNCaP cells was also studied.
ATRA inhibits LNCaP cell proliferation in a concentration-
dependent manner (Figure 4) with a calculated IC50 value of
4.3mM (Table 1). For studies of effects of combination of RAMBAs
with ATRA, we used low doses (1mM each, doses that exhibited low
[o10%] antiproliferative effects) of RAMBAs. All RAMBAs, that is,
VN/14-1, VN/50-1, VN/66-1, VN/69-1 each in combination with
ATRA, significantly enhance the antiproliferative activity of ATRA,
by 47-, 60-, 70-, 65-fold, respectively (for VN/14-1, IC50 from 10.0
to 0.092mM; for VN/50-1, IC50 from 6.0 to 0.071mM; for VN/66-1,
IC50 from 4.5 to 0.061mM; and for VN/69-1, IC50 from 5.0 to
0.066mM) (Figure 4 and Table 1). These enhancements of ATRA
activity are considered synergistic because the growth inhibitory
effects were each significantly greater than the predicted values.
Effects of the RAMBAs alone and in combination with
ATRA on LNCaP cell differentiation
Cytokeratins 8/18 are present in the differentiated luminal
epithelia in prostate and an increase in their content is considered
to indicate differentiation (Owens and Lane, 2003). To determine
the effects of these retinoids on cell differentiation, LNCaP cells
were incubated with various concentrations of ATRA or RAMBA
for 6 days; cell lysates were prepared and subjected to SDS–PAGE
gel electrophoresis. Increase in cytokeratin 8/18 expression was
used as the marker for differentiation (Peehl et al, 1993; Hsieh
et al, 1995). There was a concentration-dependent increase in the
expression of cytokeratin 8/18 in LNCaP cells treated with ATRA,
VN/14-1, VN/50-1, VN/66-1, and VN/69-1 (data not shown) and
also a significant increase in the cytokeratin 8/18 expression for 5
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Figure 2 Time course of induction of CYP26 in prostate cancer cells.
LNCaP, PC3, and DU145 cells were pre-incubated with 1mM ATRA for
various time periods to induce the CYP26 enzyme. Cells were then isolated
and incubated at 371C for 5h with 0.8mM [11,12-
3H]-ATRA. Retinoids
were extracted, and metabolites analysed by HPLC as described in
Materials and Methods. Metabolic activity was calculated as percentage of
polar ATRA metabolites of total radioactivity. The metabolic activity of
induced LNCaP, PC3, and DU145 cells was then divided by the metabolic
activity of the respective un-induced cells (percent metabolism). The
percent metabolism of each un-induced cell line was set to the x-axis
(Control) and the percent metabolism of the induced cell lines was plotted
accordingly. The experiments were performed thrice.
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sand 10mM treatment for ATRA and all RAMBAs (Po0.05)
compared to control (data not shown). This increase in cytokeratin
8/18 expression in LNCaP cells treated with ATRA and the
RAMBAs is indicative of differentiation.
For combination studies, LNCaP cells were incubated with 1mM
ATRA, alone and in combination with 1mM of RAMBA for 6 days.
Our results are summarised in Figure 5 and show significantly
increase in the expression of cytokeratin 8/18 by 1.18 to 1.38 -fold
above control (170.07, Po0.05). ATRA (1mM) in combination
with 1mM of each of the RAMBAs, except for VN/69-1, also
significantly increased the expression of cytokeratin 8/18 by 1.32–
1.59-folds above control [170.07, (Po0.05)]. Thus, most RAMBAs
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Figure 3 Inhibition of ATRA metabolism by VN/14-1 in intact LNCaP cells. Human LNCaP prostate cancer cells were cultured under basal conditions
(data not shown) or pretreated with 1mM ATRA (A–D). Thereafter, cells were washed, and incubated with 0.1mM [11,12-
3H]-ATRA, either in the absence
(A) or presence (B–D) of VN/14-1 at concentrations of 0.1, 10, and 1000nM, respectively. The cells and media were collected, extracted and analysed by
reverse phase HPLC as described in Materials and Methods. The experiments were performed twice.
Table 1 IC50 values of the RAMBAs on cellular CYP26 and LNCaP cell
growth inhibition assays
Cell growth inhibition
b
Agents
alone
Combination
with RAMBAs
c
Compound
Cellular CYP26
assay
a IC50 (nM)I C 50 (lM)I C 50 (lM)
Fold
enhancement
ATRA — 4.3 —
VN/14-1 6.571.5 10.0 0.092* +47
VN/50-1 90.0710.0 6.0 0.071* +60
VN/66-1 62.5712.5 4.5 0.061* +70
VN/69-1 90.0712.5 5.0 0.066* +65
aThe cellular CYP26 assay was performed using [11,12-
3H]-ATRA as a substrate for
CYP26 with the addition of various concentrations of each RAMBA. The retinoids
were extracted, processed, and analysed by HPLC. Percent metabolism vs the
concentration of RAMBA used was obtained and graphed. IC50 values were
determined as the concentration of RAMBA that inhibited the metabolism of
[11,12-
3H]-ATRA by 50%.
bFor cell growth inhibition studies, LNCaP cells were
incubated with various concentrations of ATRA and the RAMBAs alone and in
combination. The WST-1 assay was performed. The plot represents the percentage
of viable cells vs the concentration of RAMBA used. The IC50 value was determined
as the concentration of RAMBA that inhibited LNCaP cell viability by 50%.
c1mM of
each RAMBA was used. Statistical significance was defined at the level of *Po0.05.
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Figure 4 Antiproliferative effects of ATRA or VN/69-1 alone and ATRA
in combination with VN/69-1 (1mM). LNCaP cells were incubated with
various concentrations of ATRA, the RAMBAs alone and in combination.
The MTT assay was performed. The plot represents the percentage of
viable cells vs the concentration of agents used. The IC50 value was
determined as the concentration of agents that inhibited the viability of
LNCaP cells by 50%. Similar results were obtained for VN/14-1, VN/50-1,
VN/66-1, and 4-HPR.
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senhanced the prodifferentiation activity of ATRA in the LNCaP
cells.
TUNEL analysis of LNCaP cells treated with ATRA, 4-HPR,
and RAMBAs
One of the possible mechanisms underlying the observed effect of
ATRA and the RAMBAs on LNCaP cell viability is the direct
induction of apoptosis. To test this hypothesis, TUNEL assays were
performed following treatment of cells with the various agents.
LNCaP cells treated with 1 or 5mM ATRA, 4-HPR, or RAMBA for 6
days were processed for TUNEL staining, and viewed under
fluorescence microscopy to examine the presence of nicked DNA
that are hallmarks of apoptosis. Pictures obtained from the
staining of control, ATRA, and VN/69-1 are shown in Figure 6A
and results from the TUNEL analysis for all the test compounds are
summarised in Figure 6B. Generally, there was a concentration-
dependent induction of apoptosis in LNCaP cells treated with 1 or
5mM ATRA, 4-HPR, VN/14-1, VN/50-1, VN/66-1, and VN/69-1.
Treatment with the most potent RAMBAs, VN/14-1 and VN/50-1
(5mM), yielded a percentage of apoptotic cells of 17.03 and 17.03%,
respectively (Figure 6B).
Effects of ATRA, 4-HPR, and RAMBAs on expressions of
Bad and Bcl-2
Bcl-2 is an antiapoptotic protein and acts through inhibition of
mitochondrial cytochrome c release (Murphy et al, 2000). Bad is
pro-apoptotic and acts by displacing Bax from binding to Bcl-2
(Yang et al, 1995; Zha et al, 1996). Bax then dissipates the
mitochrondrial membrane releasing cytochrome c which leads to
apoptosis (Rosse et al, 1998). 4-HPR was used as a reference
compound as it was well established to induce apoptosis (Fontana
and Rishi, 2002). We observed a significant increase in Bad
expression for 5 and 10mM treatment with ATRA and the RAMBAs
compared with control (Po0.05), with the exception of 4-HPR,
where all treatment concentrations of 4-HPR (0.1, 1 and 5mM) were
significant (Po0.05) and VN/69-1, where treatments with 1, 5, and
10mM VN/69-1 were significant (Po0.05) (Figure 7). Our results
show that there was a concentration-dependent increase in Bad
expression in LNCaP cells treated with all of the tested agents.
Although there was a concentration-dependent decrease in the
expression of Bcl-2 in LNCaP cells treated with ATRA and VN/14-
1, treatments with 4-HPR, VN/50-1, VN/66-1, and VN/69-1,
however, did not effect Bcl-2 expression (data not shown).
Cell-cycle analysis of LNCaP cells treated with ATRA, 4-
HPR, and RAMBAs
Owing to the antiproliferative activities of these agents, it was of
interest to determine their effects on cell-cycle distribution and
apoptosis. LNCaP cells were treated with 1 or 5mM ATRA, 4-HPR,
or RAMBA for 6 days. However, only the cell-cycle analysis of
LNCaP cells treated with 5mM of the agents are shown in Figure 8
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Figure 5 Effects of ATRA and RAMBAs alone and in combination on
levels of cytokeratin 18 (a differentiation marker) in human prostate LNCaP
cells. Cells were incubated with ATRA or RAMBAs alone or in
combinations for 6 days. Lysates were subjected to SDS–PAGE and
Western blotting. Membranes were probed with cytokeratin 18 antibody,
and intensities of bands were analysed by densitometry. Groups labelled
with * are significantly different from control (Po0.05). Groups labelled
with # are significantly different from ATRA alone (Po0.05). Groups
labelled with ^ are significantly different between combination RAMBA
with ATRA compared to the corresponding RAMBA alone (Po0.05).
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Figure 6 (A) Apoptosis in LNCaP cells determined by TUNEL and
analysed by fluorescence microscopy. LNCaP cells were treated with 5mM
ATRA or RAMBA for 6 days. Cells were then fixed, stained, mounted, and
examined under fluorescence microscopy. Control is shown in a, b, and c.
ATRA (5mM) is shown in d, e, and f. VN/69-1 (5mM) is shown in g, h, and i.
Nuclear DAPI staining is shown in a, d, and g. FITC staining for nicked
DNA is shown in b, e, and h. Combined DAPI and FITC staining is shown
in c, f, and i.( B) TUNEL analysis of LNCaP cells treated with ATRA, 4-
HPR, or RAMBAs. LNCaP cells were incubated with either 1 or 5mM of
ATRA, 4-HPR, or a RAMBA for 6 days. LNCaP cells were then fixed,
stained, mounted, and analysed by fluorescence microscopy. The number
of apoptotic cells and total number of cells were counted in each of the five
fields for each treatment and the percentage of apoptotic cells was
calculated and plotted. Treatment with 1mM drugs significantly increased
from its control (*) (Po0.05). Treatment with 5mM drugs significantly
increased from its control (#) (Po0.05). Treatment with 5mM of drugs
significantly increased from 1mM of the same drug (^) (Po0.05).
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sand also summarised in Table 2. With these treatments, there was
no change in the percentage of cells in the G0/G1 phase (except for
ATRA treatment), a decrease in the percentage of cells in the S
phase, and an increase in the percentage of cells in the G2/M phase
(a G2/M cell arrest, Table 2). There was also an increase in the
percentage of cell in the sub-G1 phase that indicates apoptotsis in
LNCaP cells treated with these agents.
The effects of ATRA and RAMBAs in LNCaP xenograph
SCID mouse model
We next tested the effects of our RAMBAs on growth inhibition of
LNCaP tumour xenographs. Male SCID mice bearing LNCaP
tumour xenographs (approximately 100mm
3) were grouped and
treated once daily with 0.033mmolkg
 1 each of ATRA or RAMBAs
for the indicated time periods. As treatment with VN/50-1 was very
toxic to the mice, experiment with this cohort was terminated.
Tumour growth in the group receiving VN/14-1 was not
significantly different from that observed in the vehicle control
group (Figure 9). Mice receiving VN/66-1 or VN/69-1 had 44 and
47%, respectively, reduction in tumour growth compared to
control (Po0.05), whereas treatment with ATRA reduced tumour
growth by 75% relative to control (Po0.05) (Figure 9). During the
study, all mice were weighed twice a week. Whereas the body
weights of mice in the RAMBAs-treated groups were not altered,
weights of mice in the ATRA-treated group were significantly
(B25%) reduced compared to control (data not shown).
DISCUSSIONS
The prompt emergence of resistance to ATRA therapy in oncology
and dermatology is a major concern in the development of ATRA
(Miller, 1998; Njar, 2002, 2006). Agents that are able to inhibit
ATRA metabolism may be used alone or in combination with low
doses of ATRA or other therapeutic agents for the treatment of a
variety of cancers and dermatological diseases. Interest in the
development of structurally diverse agents as RAMBAs has
increased over the last 5 years. We have developed several atypical
RAMBAs with retinoidal scaffolds that possess unique multiple
biological activities (Patel et al, 2004, 2006; Belosay et al, 2005;
Njar, 2006). In this study, we have investigated the effects and
mechanisms of action of several of these RAMBAs in human
prostate LNCaP carcinoma cells.
Han and Choi (1996) were able to induce ATRA 4-hydroxylase
in T47D cells and suggested that ATRA induces its own
metabolism through a negative feedback mechanism. The enzyme
activities induced by ATRA appear to be regulated at the level of
transcription. Our results showed that only LNCaP cells were able
to metabolise ATRA through induction of CYP26 (Figure 2). PC3
cells did not metabolise ATRA and the metabolism of ATRA did
not exceed basal levels despite induction of CYP26 in DU145 cells.
These results suggest that hormone-dependent cells (LNCaP) are
able to metabolise ATRA following induction of CYP26 and that
hormone-independent cells (PC3 and DU145) are not. To the best
of our knowledge, this appears to be the first report of induction of
ATRA 4-hydroxylase (CYP26) in LNCaP cells. The lack of ATRA-
induced CYP26 in both PC3 and DU145 cells may be due to the
loss of RARs in these cell lines. Several investigators have reported
that the loss of RAR signaling in many epithelial tumours is driven
by loss of expression of RARs (Campbell et al, 1998; Zhang, 2002).
Based on the IC50 values of the RAMBAs in hamster hepatic
microsomes that were obtained previously (Patel et al, 2004),
representative RAMBAs (VN/14-1, VN/50-1, VN/66-1, and VN/69-
1) (Figure 1) were studied further in LNCaP cells. In intact LNCaP
cells, these compounds potently inhibit ATRA metabolism (Figure
3C–D and Table 1). The IC50 values obtained for VN/14-1, VN/66-
1, and VN/69-1 were comparable to the values seen in cellular
MCF7 and T47D breast cancer cells that were determined
previously (Patel et al, 2004). However, there was a discrepancy
in the IC50 value for VN/50-1 (10.0nM in T47D cells vs 90.0nM in
LNCaP cells). This difference may be due to the ability of VN/50-1
to penetrate the cell membranes of the LNCaP PCA cells. Similar
results have recently been reported for farnesol derivatives that are
weak inhibitors of ATRA metabolism in human head and neck
squamous cell carcinoma (AMC-HN-6) cells and their microsomal
preparations (Kim et al, 2001).
In LNCaP cell proliferation experiments, each of the RAMBAs
tested enhanced the antiproliferative activity of ATRA (Figure 4
and Table 1). The antiproliferative effects of ATRA was enhanced
by 47- to 70-fold with the addition of 1mM VN/14-1, VN/50-1, VN/
66-1, or VN/69-1. Concentrations of RAMBAs effective in
enhancing the antiproliferative activity of ATRA are themselves
unable to significantly decrease LNCaP cell proliferation. Thus,
these data support the hypothesis that our compounds enhance the
biological activity of ATRA through inhibition of ATRA metabo-
lism. These results are identical with those previously observed in
human breast MCF-7 cancer cells (Patel et al, 2004), but are
ATRA
4-HPR
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Figure 7 Western immunobloting of whole-cell lysates of treated
LNCaP cells for expression of Bad. Cell lysates were used as described in
the differentiation assay. Bad is a proapoptotic protein. The Western blots
of Bad expressions are shown. The lanes are labelled above the blots and
the expression of Bad is expressed as fold over control as determined by
densitometry (below the blot). There was a significant difference in groups
labelled with * compared to control (Po0.05).
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ssuperior to the effects observed with R116010 in human breast
T47D cancer cells (Van Heusden et al, 2002). In the latter study,
R116010, at a concentration of 1mM, enhanced the antiproliferative
activity of ATRA only by threefold. As expected, our RAMBAs also
inhibited the growth of LNCaP cells in a dose-dependent manner,
with IC50 values ranging from 4.3 to 10mM (Figure 4 and Table 1),
which correlates with their intrinsic retinoidal antiproliferative
activities.
Having established the in vitro antiproliferative activities of
these novel compounds alone and in combination with ATRA, we
set out to investigate possible molecular mechanisms that might be
involved using established procedures. On the basis of our
previous studies and knowledge that these RAMBAs possess both
intrinsic retinoid-like activities and also ATRA-mimetic effects
(Patel et al, 2004), we assessed their effects on cell differentiation,
apoptosis and cell cycle.
Indeed, this study presents evidence that our RAMBAs induce
differentiation (via upregulation of cytokeratin 8/18 expression)
and also significantly enhance ATRA-induced differentiation in the
LNCaP cells. We have previously shown that with the exception of
VN/14-1, the other three RAMBAs were weak ligands and
activators of the RARa. As it is believed that only ligands that
activate RARa induce cell differentiation (Bollag et al, 1997), the
present data suggest that induction of differentiation can also
occur via RARa-independent pathway. The ability of the RAMBAs
to enhance ATRA-induced differentiation may be attributed to
intracellular inhibition of ATRA metabolism with concomitant
accumulation of cellular ATRA.
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Figure 8 Cell-cycle analysis of LNCaP cells treated with 1 or 5mM ATRA, 4-HPR or RAMBAs. LNCaP cells were incubated with either 1 or 5mM ATRA,
4-HPR, or RAMBA for 6 days. LNCaP cells were then fixed, stained with propidium iodide, and analysed by FACScan. Histograms of the FACScan analysis
from control (A), ATRA (B), 4-HPR (C), VN/14-1 (D), VN/50A-1 (E), VN/66-1 (F), and VN/69-1 (G) are shown.
Table 2 Cell-cycle analysis of LNCaP cells treated with 1 or 5mM ATRA,
4-HPR or RAMBAs
Treatment G0/G1 (%) S (%) G2/M (%) Sub-G1 (%)
Control 82.78 15.01 2.20 9.02
ATRA (5mM) 77.74 9.84 12.42 13.64
4-HPR (1mM)
a 79.53 9.18 12.03 7.52
VN/14-1 (5mM) 82.59 7.26 10.15 17.88
VN/50-1 (5mM) 81.33 11.38 7.30 17.67
VN/66-1 (5mM) 83.80 11.14 5.07 14.49
VN/69-1 (5mM) 82.66 11.14 6.20 13.39
LNCaP cells were incubated with either 1 or 5mM ATRA, 4-HPR, or RAMBA for 6
days. LNCaP cells were then fixed and stained with propidium iodide. 10
4 LNCaP
cells were analysed by FACScan. The percentages of cells in the G0/G1, S, and G2/M
were calculated from diploid cells. The percentage of apoptotic cells (sub G0/G1)w a s
calculated from the total number of cells minus the debris. The percentages of cells in
G0/G1, S, and G2/M phases of the cell cycle as well as percentage of apoptotic cells
(sub-G1) were determined using MODFIT LT software.
aTreatment with 5mM 4-HPR
resulted in a massive amount of cell death such that no cell-cycle analysis could be
performed.
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sIn the normal prostate, there is a balance between cell
proliferation and cell death (Denmeade et al, 1996), while in
PCA, the proliferative rate remains relatively low, but there is less
apoptosis (Berges et al, 1995). Our results here demonstrate that
RAMBAs were able to induce apoptosis in LNCaP cells as
determined by the TUNEL assay. Induction of apoptosis appears
to be associated with upregulation of the proapoptotic protein Bad
and reduction or no change in the levels of antiapoptotic Bcl-2.
Furthermore, cell-cycle analysis revealed that these agents
significantly induce arrest of cell in the G2/M phase. It should be
stated that there is a major checkpoint in the G2/M phase of the cell
cycle where cells arrested in the G2/M phase can undergo apoptosis
if optimal conditions are not met (Kastan and Bartek, 2004). This
scenario may also be operational in this study. Therefore, our
findings that our RAMBAs cause G2/M arrest and induce apoptosis
in the LNCaP cells offer a potential new therapeutic option for PCA
therapy.
The marked effects that our RAMBAs had on cell proliferation
led to in vivo studies. Our in vivo studies showed that VN/14-1 was
ineffective in this model as it did not cause inhibition of tumour
growth (Figure 9). VN/50-1 was toxic to the animals and its
antitumour efficacy could not be assessed. The lack of antitumour
efficacy of VN/14-1 in the LNCaP PCA model is rather puzzelling
because the compound has been shown to possess excellent
antitumour efficacy in the MCF-7 human breast cancer model
(Patel et al, 2004, 2006). Clearly, more studies are required to
explain this unexpected finding. In contrast to the effects of VN/
14-1, the other two RAMBAs, VN/66-1 and VN/69-1 as well as
ATRA exhibited statistically significantly LNCaP tumour growth
inhibition. Despite the fact that ATRA exhibited a more potent
antitumour activity, the significant decrease (25%) in body weights
of animals in this cohort is indicative of toxicity, which is a matter
of concern. Although a first generation RAMBA, liarozole has been
shown to exhibit potent antitumour efficacy against human
androgen-independent PCA tumours, such as PC-3ML-B (Stearns
et al, 1993), and DU-145 (Smets et al, 1994) and several rat PCA
tumours (De Coster et al, 1992; Dijkman et al, 1994); this
study appears to be the first report on the antitumour efficacy
of RAMBAs against human androgen-dependent LNCaP PCA
tumours. Recently, it was demonstrated that a second generation
RAMBA, R116010, was able to significantly inhibit the growth
of murine TA3-Ha mammary tumours in A/J mice (Van Heusden
et al, 2002). Given that our RAMBAs exhibited potent in vitro
antiproliferative activities, their in vivo antitumour efficacies
are rather disappointing. The reason(s) for these discrepancies
are unknown at this time but could be caused by the rapid
metabolism of the various RAMBAs to inactive metabolites in vivo
or the combined effects of RAMBAs and endogenous constituents
that, in combination with the RAMBAs exert poor inhibitory
effects on tumour growth. Clearly, further in vivo studies using
other doses of the RAMBAs and modes of administrations are
necessary to determine fully the usefulness of these novel
compounds in PCA.
In conclusion, we have identified potent inhibitors of ATRA
metabolism in intact human LNCaP PCA cells. Inhibition of ATRA
metabolism leads to enhanced antiproliferative activity of ATRA
both in vitro and in vivo. This report, to our best knowledge, is the
first to demonstrate the induction of cell differentiation, apoptosis
and G2/M cell cycle arrest by RAMBAs in human PCA cells. Our
findings suggest that additional studies to determine the efficacy of
our novel RAMBAs in the treatment of human prostate cancer are
warranted.
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